Antihyperlipidemia.

Slides:



Advertisements
Similar presentations
Agents Used in the Treatment of Hyperlipidemia
Advertisements

Drugs in dyslipidaemias
CHOLESTEROL AND OUR LIVES الدهنيات وحياتنا
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Lipids 101 Cardiology Board Review Med-Peds Style!
Drugs and Dyslipidemias (statins and other lipid and atherosclerosis-modifying drugs) October 18, 2006 Frank F. Vincenzi.
Diagnosis and Treatment of Dyslipidemia  New guidelines are based on the “Adult Treatment Plan III (ATP III)” 2004  Focus = multiple risk factor assessment.
Treatment of Dyslipidemia SDPI CGP Healthy Heart Project March 8, 2006.
Cholesterol.
LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL)
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 50 Prophylaxis of Coronary Heart Disease: Drugs That Help Normalize Cholesterol.
Anti-Hypercholesterolemic Agents  Biosynthesis and Metabolism of Cholesterol  What is arteriosclerosis? - Link between arteriosclerosis and cholesterol.
ANTILIPEMICS LILLEY, READING & WORKBOOK: CHAP 28 Cardiovascular System.
Pharmacology of Agents Used in Hyperlipidemia
Antiatherosclerosis drugs. Lipid-regulating drugs  Background  Lipoprotein  Classification of Lipoprotein: CM 、 VLDL 、 IDL 、 LDL 、 HDL 、 Lp(a) CM 、
1 Drugs for Hyperlipidemia Lipids are necessary for human life Cholesterol –Essential component of cell membrane –Precursor to the sterol and steroid compounds.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 29 Antilipemic Drugs.
The Antihyperlipidemic Medications l Classifications of Lipoproteins – Chylomicrons l Formed in the mucosal cells of the gut l Protein coated dietary lipids.
Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display. 1 CHAPTER 29 Hypolipidemic Drugs.
Kirk Mykytyn, Ph.D. Department of Pharmacology
Department of Family & Community Medicine
Agents Used to Treat Hyperlipidemia. Hyperlipidemia 2 Atherosclerosis – accumulation of fatty substances on the inner wall of large and medium sized arteries.
Hyperlipidemia Hyperlipoproteinemia Hyperlipoproteinemia (cholesterol, Triglyceride, LDL-C, VLDL) Lead to atherosclerosis and Coronary artery disease.
ANTIHYPERLIPIDEMIC DRUGS
Nutrition & Heart Disease Key Concepts and Facts Heart disease is leading cause of death Dietary and lifestyle factors are important Diets that provide.
Hperlipidemia:- Treatment and Management Presented by:- Dr. Tewari.
Lecture 5b 3 Feb 2014 Atherosclerosis-Nutritional intervention- -emphasis should be on prevention-
Management & Medications  Diet, weight loss and drug therapy are the mainstay of treatment, while exercise training is used as adjunctive therapy  Lipid-lowering.
Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein.
Chapter 19 Agents Used to Treat Hyperlipidemia. Hyperlipidemia 2 Atherosclerosis – accumulation of fatty substances on the inner wall of large and medium.
HYPERLIPIDEMIA Dan O’Connell, MD Montefiore Family Medicine August 2004.
HYPERLIPIDEMIA Applied Therapeutics Dr. Riyadh Mustafa Al-Salih.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 28 Antilipemic Drugs.
HLD Tx & AHA/ACC Guidelines
Adult Treatment Panel III (ATP III) Guidelines Hyperlipidemia.
Hyperlipidemia Hyperlipidemia and hyperlipoproteinemia are general terms for elevated concentrations of lipids and lipoproteins in the blood. hypercholesterolemia.
Management of Hyperlipoprotinaemia
1 HYPOLIPIDAEMICS or LIPID LOWERING DRUGS. 2 Hypolipidaemic agents, or antihyperlipidemic agents, are a diverse group of pharmaceuticals that are used.
Chapter 21 Agents Used in the Treatment of Hyperlipidemia.
Drugs Used to Treat Dyslipidemias Chapter 22 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Case 4 Chang Chia-Chieh(Tony). Mr. Reyes was prescribed Lovastatin 20mg. b.i.d. and told to return in 6 weeks.
LAB (6): LIPIDS PROFILE KAU-Faculty of Science- Biochemistry department Clinical biochemistry lab (Bioc 416) 2013.
Anti hyperlipidemic drugs (lipid lowering drugs) Department of Pharmacology Faculty of Medicine AIMST UNIVERSITY 5 September 2012.
HYPERLIPIDEMIA  Coronary heart disease (CHD) is the cause of about half of all deaths. The incidence of CHD is correlated with elevated levels of low-density.
 Define cholesterol.  Discuss the purpose of lipoproteins.  Distinguish between LDL and HDL.
50 Drugs that Help Normalize Cholesterol & Triglyceride Levels
Prophylaxis of Coronary Heart Disease: Drugs That Help Normalize Cholesterol and Triglyceride Levels.
Drugs Used in Hyperlipidemia
Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease Department of Nephrology R3. Yeehyung Kim.
Antihyperlipidemic Drugs
Chapter 18 Drugs Used to Lower Lipids
أبدا لم يفت الاوان لكي تبدأ
Drugs for Lipid Disorders
Anti-Hypercholesterolemic Agents
By: Dr Israa Omar MBBS, MRCP, MSc pharmacology
Applied Therapeutics Dr. Riyadh Mustafa Al-Salih
18 Dyslipidemia Lect -2- Dr.Hozan.
Anti-Hypercholesterolemic Agents
Drugs for Hyperlipidemias
Biosynthesis and Metabolism of Cholesterol
Antilipidaemic agents
Antihyperlipidemic Drugs
Patients aged 85yrs and over
Cardiovascular System
Antilipemic Agents Lilley Pharmacology Text: Chapter 27
Lecture 5b 7 Feb 2011 Atherosclerosis-Nutritional intervention-
Introduction to Clinical Pharmacology Chapter 34 Antihyperlipidemic Drugs.
Hyperlipidemia (Hyperlipoproteinaemia) (Dyslipidemia) By Ahmed M
ATP III Guidelines Drug Therapy FUTURE RESEARCH.
Specific Dyslipidemias: Very High LDL Cholesterol (>190 mg/dL)
Presentation transcript:

Antihyperlipidemia

Definition : Definition Hyperlipidemia, hyperlipoproteinemia or dyslipidemia is the presence of raised or abnormal levels of lipids and/or lipoproteins in the blood Lipids are insoluble in aqueous solution. Lipids (fatty molecules) are transported in a protein capsule, and the density of the lipids and type of protein determines the fate of the particle and its influence on metabolism. Lipid and lipoprotein abnormalities are extremely common in the general population, and are regarded as a highly modifiable risk factor for cardiovascular disease due to the influence of cholesterol, one of the most clinically relevant lipid substances, on atherosclerosis.

Pathobiology of Atherosclerosis When excess cholesterol deposits on cells and on the inside walls of blood vessels it forms an atherosclerotic plaque The first step of atherosclerosis is injury to the endothelium which results in atherosclerotic lesion formation When the plaque ruptures, blood clots form which lead to decreased blood flow, resulting in cardiovascular events

Complications of Hyperlipidemia Macrovascular complications: Unstable Angina (chest pain) Myocardial Infarction (heart attack) Ischemic Cerebrovascular Disease (stroke) Coronary Artery Disease (heart disease) Microvascular complications: Retinopathy (vision loss) Nephropathy (kidney disease) Neuropathy (loss of sensation in the feet and legs)

Risk Factors for Hyperlipidemia Obesity Type 2 diabetes mellitus Advanced age Hypothyroidism Obstructive liver disease Genetics Drug induced: (e.g. glucocorticoids, thiazide diuretics, beta blockers, protease inhibitors, sirolimus, cyclosporine, progestins and alcohol)

Treatment Goals : Reduce total cholesterol and LDL (bad) cholesterol Prevent the formation of atherosclerotic plaques and stop the progression of established plaques Prevent heart disease Prevent morbidity and mortality

Non-Pharmacological Treatment : Lipid lowering therapy should be started with lifestyle modification for at least 12 weeks Increase physical activity Weight reduction Diet modification: Total fat 25-35% of total calories Saturated fat <7% of total calories Polyunsaturated fat up to 10% total calories Monounsaturated fat up to 20% total calories Carbohydrates 50-60% total calories Fiber 20-30 g/ day total calories Protein 15% total calories Cholesterol <200 mg/day

Pharmacological Treatment : Pharmacological Treatment If non-pharmacological treatment is not successful, a lipid-lowering drug should be started, especially in high risk populations 1st step: Initiate LDL-lowering drug therapy . Start with statins, bile acid sequestrants, or nicotinic acid. Evaluate after 6 weeks . 2nd step: If goal was not reached, intensive lipid-lowering treatment should be started . Increase dose of statins . Bile acid sequestrants or nicotinic acid should be added. 3rd step: If goal is not reached, intensive lipid lowering should be continued or individual should be referred to a lipid specialist . If goal was reached, other lipid risk factors should be treated . 4th step: Monitor response and compliance.

Pharmacological Treatment Statins (HMG CoA Reductase Inhibitors) Atorvastatin (Lipitor® ) Simvastatin (Zocor®) Lovastatin (Mevacor®): extended release Pravastatin (Pravachol®) Fluvastatin (Lescol®) Lescol XL: 80 mg tablets . Rosuvastatin (Crestor®): tablets

Statins (HMG CoA Reductase Inhibitors) Effectiveness of statins: Reduce LDL cholesterol by 18-55% Decrease TG by 7-30% Raise HDL cholesterol by 5-15% Statins are the most effective in lowering LDL cholesterol Statins are the most effective in patient who has low HDL and high LDL

Statins (HMG CoA Reductase Inhibitors) Mechanism of action: Statins inhibit HMG-CoA reductase (enzyme involved in cholesterol synthesis) thus decreasing mevalonic acid production and stimulating LDL breakdown.

Statins (HMG CoA Reductase Inhibitors) Side effects: Muscle break down (rhabdomyolysis) Increased liver enzymes leading to renal failure Fatigue, mild stomach disturbances, headache, or rash

Statins (HMG CoA Reductase Inhibitors) Avoid use in: Active or chronic liver disease and pregnancy Use with caution with: Concomitant use of cyclosporine, macrolide antibiotics, antifungal agents. For example: Itraconazole, ketoconazole, erythromycin, clarithromycin, cyclosporine, nefazodone, HIV antiretrovirals When statins are used with fibric acids and niacin, appropriate caution should be taken because of increasing incidence of muscle breakdown

Statins (HMG CoA Reductase Inhibitors) Drug- food interaction: Grapefruit juice increases concentration of statins Pravastatin, rosuvastatin & fluvastatin concentrations are not affected by grapefruit juice. Monitoring: Muscle soreness, tenderness, or pain. Liver function tests : baseline, 4-6 weeks after starting therapy, and then annually. Muscle enzyme levels when individual has muscle pain

Pharmacological Treatment: 2. Bile Acid Sequestrants Mechanism of action: Bile acid sequestrants bind to bile acids in the intestine, thus inhibits uptake of intestinal bile salts into the blood and increases the fecal loss of bile salt-bound LDL

Bile Acid Sequestrants: 1) Cholestyramine (Questran®): Usual dose: 4 g by mouth 1-2 times a day with meal to a maximum of 24 g per day. 2) Colesevelam (Welchol®): Usual dose: 3 tablets by mouth twice daily with meals or 6 tablets once daily with a meal. 3) Colestipol (Colestid®) Usual dose: Granules: 5-30 g by mouth daily given once or 2-4 times a day with meal Tablets: 2-16 g by mouth daily.

Bile Acid Sequestrants: Effectiveness: Reduces LDL cholesterol by 15-30% Increases HDL cholesterol by 3-5% Increases TG. Drug interaction: Decreased absorption of fat soluble Vitamins: A, D, E, K, C and folic acid Decreased absorption of other drugs: tetracycline, thiazide diuretics, aspirin, phenobarbital, pravastatin, digoxin

Bile Acid Sequestrants: Side effects: Stomach upset, constipation accompanied by heart burn, nausea, and bloating Avoid use in: A disease called dysbetalipoproteinemia Triglycerides >400 mg/dL Use caution if: Triglycerides >200 mg/dL. Colesevalam is much better tolerated than cholestyramine or colestipol Statins and other drugs should be taken 1-2 hours before and 4-5 hours after bile acid sequestrants

Pharmacological Treatment: 3) Nicotinic Acid: Mechanism of action: Nicotinic acid decreases the clearance of ApoA1 to increase HDL; it inhibits the synthesis of VLDL Effectiveness: Decreases LDL cholesterol by 5-25 % Increases HDL cholesterol by 15-35% Decreases TG by 20-50% Nicotinic acid is the most potent drug that increases HDL cholesterol

Nicotinic Acid: Side effects: Avoid use in: Use with caution in: Flushing (taking aspirin or ibuprofen can reduce symptoms) Increases blood glucose due to impaired insulin sensitivity Gout Liver toxicity associates with sustained release form (Niaspan) Upper stomach distress and muscle weaknes Avoid use in: Chronic liver disease Severe gout Use with caution in: Type 2 diabetes (high dose) Peptic ulcer disease

Pharmacological Treatment: 4) Fibric Acids : Mechanism of action: Fibric acid up-regulates fatty acid transport protein and fatty acid oxidation; thus it reduces the formation of VLDL, increases formation of HDL, and enhances the breakdown of TG Agents: Gemfibrozil (Lopid®) Fenofibrate (Tricor®)

Fibric Acids: Effectiveness: Reduces LDL cholesterol by 20-50% with normal TG Increases LDL cholesterol with high TG Reduces TG by 20-50% Increases HDL cholesterol by 10-20% Fibric acids are very effective in lowering TG and preventing pancreatitis Fibric acids reduce VLDL, but fibric acids might increase LDL and total cholesterol

Fibric Acids: Side effects: Avoid use in: Drug interaction: Dyspepsia, gallstones, muscle ache, rash Unexplained non-coronary heart disease deaths Weakness, tiredness, elevations in muscle enzyme Avoid use in: Severe renal disease Severe hepatic disease Drug interaction: Fibric acids bind to albumin and increase the effect of anticoagulants

Pharmacological Treatment: 5) Ezetimibe (Zetia) Mechanism of action: Inhibits absorption of cholesterol in the small intestine; thus it decreases the delivery of cholesterol to the liver and increases the clearance of cholesterol from the blood Side effects: chest pain, dizziness, diarrhea, abdominal pain Drug interaction: Bile acid sequestrants decrease ezetimibe concentrations Ezetimibe should be spaced 2 hours before or 4 hours after bile acid sequestrants administration Fibric acids increase ezetimibe concentrations